Lisa Christopher-Stine

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5817826/lisa-christopher-stine-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128 papers

4,745 citations

35 h-index 65 g-index

145 ext. papers

6,304 ext. citations

avg, IF

5.84 L-index

#	Paper	IF	Citations
128	Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
127	Patient Perceptions and Preferences Regarding Telemedicine for Rheumatologic Care during the COVID-19 Pandemic <i>Arthritis Care and Research</i> , 2022 ,	4.7	1
126	Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease <i>Lancet Rheumatology, The</i> , 2022 ,	14.2	5
125	On the Nose: Anti-MDA-5 Dermatomyositis Manifesting as Perinasal Swelling <i>Case Reports in Dermatology</i> , 2022 , 14, 1-5	1.1	
124	Myositis-specific antibodies: Overview and clinical utilization. <i>Rheumatology and Immunology Research</i> , 2022 , 3, 1-10	0.2	O
123	Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021, 7, 86	51.1	7
122	A North American Cohort of Anti-SAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. <i>ACR Open Rheumatology</i> , 2021 , 3, 287-294	3.5	4
121	Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. <i>Clinical Rheumatology</i> , 2021 , 40, 4095-4100	3.9	0
120	Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. <i>Rheumatology</i> , 2021 , 60, e387-e388	3.9	3
119	High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1351-1352	2.4	57
118	Risk Factors For Infection And Health Impacts Of The Covid-19 Pandemic In People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	7
117	Anti-cortactin autoantibodies are associated with key clinical features in adult myositis but are rarely present in juvenile myositis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
116	Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. <i>Rheumatology</i> , 2021 , 60, 692-698	3.9	2
115	Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. <i>Arthritis and Rheumatology</i> , 2021 , 73, 858-865	9.5	27
114	RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES 2021 ,		2
113	Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1365-1366	2.4	10
112	Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. <i>Arthritis and Rheumatology</i> , 2021 , 74, 28	9.5	22

(2020-2021)

111	Long Term Extension Study of Tofacitinib in Refractory Dermatomyositis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	O
110	A network of core and subtype-specific gene expression programs in myositis. <i>Acta Neuropathologica</i> , 2021 , 142, 887-898	14.3	O
109	Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	26
108	Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series. <i>Annals of Internal Medicine</i> , 2021 , 174, 13	83 <mark>2</mark> -133	34 ²⁶
107	Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination. <i>Lancet Rheumatology, The</i> , 2021 , 3, e753-e754	14.2	6
106	Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	21
105	Exploring Dermatomyositis through an Interdisciplinary Lens: Pearls from Dermatology and Rheumatology <i>International Journal of Womena Dermatology</i> , 2021 , 7, 576-582	2	
104	Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	3
103	The aetiopathogenic significance, clinical relevance and therapeutic implications of vasculopathy in idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2021 , 60, 1593-1607	3.9	2
102	The indirect immunofluorescence assay autoantibody profiles of myositis patients without known myositis-specific autoantibodies. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 519-524	2.2	
101	Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 351-356	2.2	1
100	Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1234-1242	2.4	23
99	Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 943-948	5.3	1
98	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2020 , 72, 529-556	9.5	135
97	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis Care and Research</i> , 2020 , 72, 461-488	4.7	54
96	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight, 2020, 5,	9.9	23
95	IgM autoantibodies recognizing ACE2 are associated with severe COVID-19 2020 ,		16
94	Pregnancy in myositis and scleroderma. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 64, 59-67	4.6	11

93	Validation of anti-Mi2 autoantibody testing by line blot. <i>Autoimmunity Reviews</i> , 2020 , 19, 102425	13.6	3
92	Dysphagia in Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2020 , 99, 404-408	2.6	10
91	Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. <i>Journal of Managed Care & Decial Pharmacy</i> , 2020 , 26, 1424-1433	1.9	3
90	Ultra-efficient sequencing of T Cell receptor repertoires reveals shared responses in muscle from patients with Myositis. <i>EBioMedicine</i> , 2020 , 59, 102972	8.8	2
89	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020 , 30, 70-92	2.9	53
88	Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. <i>Arthritis and Rheumatology</i> , 2020 , 72, 192-194	9.5	21
87	Ultrasound can differentiate inclusion body myositis from disease mimics. <i>Muscle and Nerve</i> , 2020 , 61, 783-788	3.4	8
86	More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. <i>Neurology</i> , 2019 , 93, e1768-e1777	6.5	20
85	Identification of distinctive interferon gene signatures in different types of myositis. <i>Neurology</i> , 2019 , 93, e1193-e1204	6.5	39
84	Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Statin-Associated Immune-Mediated Necrotizing Myopathy: A Case Series. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1723-172	2 8 ·5	17
83	The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2019 , 150, 63-65	4.6	8
82	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. <i>Neurology</i> , 2019 , 92, e1416-e1426	6.5	16
81	Myositis Autoantigen Expression Correlates With Muscle Regeneration but Not Autoantibody Specificity. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1371-1376	9.5	14
80	OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2019 , 46, 1351-1354	4.1	13
79	Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. <i>Muscle and Nerve</i> , 2019 , 59, 70-75	3.4	8
78	Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. <i>Chest</i> , 2019 , 156, 896-906	5.3	40
77	Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. <i>Clinical Rheumatology</i> , 2019 , 38, 1477-1483	3.9	7
76	Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. <i>Journal of Rheumatology</i> , 2019 , 46, 106-111	4.1	12

75	Clinical features related to statin-associated muscle symptoms. <i>Muscle and Nerve</i> , 2019 , 59, 537-543	3.4	7	
74	Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 858-861	2.2	3	
73	Mitochondrial DNA Deletions With Low-Level Heteroplasmy in Adult-Onset Myopathy. <i>Journal of Clinical Neuromuscular Disease</i> , 2018 , 19, 117-123	1.1	4	
72	Calcinosis of the Mandible in Dermatomyositis. Arthritis and Rheumatology, 2018, 70, 1353	9.5	2	
71	Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies. <i>Current Rheumatology Reports</i> , 2018 , 20, 27	4.9	20	
70	Update on outcome assessment in myositis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 303-318	8.1	55	
69	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 504-512	5.3	19	
68	Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 552-556	5.3	46	
67	Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. <i>Neurology</i> , 2018 , 90, e2068-e2076	6.5	41	
66	Triggers of inflammatory myopathy: insights into pathogenesis. <i>Discovery Medicine</i> , 2018 , 25, 75-83	2.5	18	
65	Pattern of muscle involvement in inclusion body myositis: a sonographic study. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 996-1002	2.2	11	
64	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 241-250	2.4	20	
63	Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. <i>Arthritis Care and Research</i> , 2017 , 69, 263-270	4.7	74	
	Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in			
62	Dermatomyositis Patients. Arthritis Care and Research, 2017 , 69, 1771-1776	4.7	85	
62		4·7 6.5	28	
	Dermatomyositis Patients. <i>Arthritis Care and Research</i> , 2017 , 69, 1771-1776 Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.			
61	Dermatomyositis Patients. <i>Arthritis Care and Research</i> , 2017 , 69, 1771-1776 Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. <i>Neurology</i> , 2017 , 88, 1454-1460 Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. <i>Annals of the Rheumatic</i>	6.5	28	

57	Statin-associated immune-mediated myopathy: biology and clinical implications. <i>Current Opinion in Lipidology</i> , 2017 , 28, 186-192	4.4	16
56	A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. <i>Rheumatology</i> , 2017 , 56, 999-1007	3.9	109
55	Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 24	7.3	25
54	Immune-mediated necrotizing myopathy associated with statins: history and recent developments. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 604-611	5.3	21
53	Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. <i>Respiratory Medicine</i> , 2017 , 130, 52-54	4.6	15
52	Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study. <i>Journal of Rheumatology</i> , 2017 , 44, 1683-1687	4.1	13
51	Autoimmune Necrotizing Myopathies: Subtypes and Advances in Treatment. <i>Current Treatment Options in Rheumatology</i> , 2017 , 3, 267-274	1.3	
50	A case of refractory dermatomyositis responsive to tofacitinib. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, e19	5.3	49
49	Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 671-673	2.2	34
48	Cytosolic 5PNucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. <i>Arthritis Care and Research</i> , 2016 , 68, 66-71	4.7	71
47	PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjgrenß syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1145-51	2.4	28
46	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. <i>Journal of Neuromuscular Diseases</i> , 2016 , 3, 67-75	5	31
45	Statin-Induced Anti-HMGCR-Associated Myopathy. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 234-5	15.1	32
44	Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. <i>Lung</i> , 2016 , 194, 733-7	2.9	70
43	Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 880-884	2.2	6
42	Genetic and immunologic susceptibility to statin-related myopathy. <i>Atherosclerosis</i> , 2015 , 240, 260-71	3.1	26
41	The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. <i>Muscle and Nerve</i> , 2015 , 52, 189-95	3.4	58
40	Idiopathic Inflammatory Myopathy Treated With High-Dose Immunoablative CyclophosphamideA Long-term Follow-up Study. <i>JAMA Neurology</i> , 2015 , 72, 1205-6	17.2	5

39	Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management. <i>Current Rheumatology Reports</i> , 2015 , 17, 72	4.9	69
38	PatientsPExperience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015 , 42, 2492-5	4.1	18
37	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e172	9.1	31
36	The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2015 , 42, 1448-54	4.1	29
35	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). <i>Current Respiratory Medicine Reviews</i> , 2015 , 11, 175-183	0.3	24
34	Polymyositis and dermatomyositis: novel insights into the pathogenesis and potential therapeutic targets. <i>Discovery Medicine</i> , 2015 , 19, 463-70	2.5	7
33	Patient-reported outcomes and adult patientsPdisease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. <i>Journal of Rheumatology</i> , 2014 , 41, 581-92	4.1	20
32	Brief report: antisynthetase syndrome-associated myocarditis. <i>Journal of Cardiac Failure</i> , 2014 , 20, 939-	45 3	18
31	Inclusion body myositis: update. Current Opinion in Rheumatology, 2014, 26, 690-6	5.3	15
30	Identifying statin-associated autoimmune necrotizing myopathy. <i>Cleveland Clinic Journal of Medicine</i> , 2014 , 81, 736-41	2.8	21
29	Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. <i>Arthritis Care and Research</i> , 2013 , 65, 1307-15	4.7	180
28	Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\(\textit{l} Arthritis and Rheumatism, \textit{2013}, 65, 2954-62		237
27	1H Magnetic resonance spectroscopy findings in idiopathic inflammatory myopathies at 3 T: feasibility and first results. <i>Investigative Radiology</i> , 2013 , 48, 509-16	10.1	16
26	Case records of the Massachusetts General Hospital. Case 37-2012. A 21-year-old man with fevers, arthralgias, and pulmonary infiltrates. <i>New England Journal of Medicine</i> , 2012 , 367, 2134-46	59.2	11
25	Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. <i>Arthritis Care and Research</i> , 2012 , 64, 1233-7	4.7	79
24	Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. <i>Arthritis and Rheumatism</i> , 2012 , 64, 4087-93		159
23	Novel approaches in the treatment of myositis and myopathies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 369-77	3.8	11
22	Expanding our understanding of statin myopathy: when is it autoimmune?. <i>International Journal of Clinical Rheumatology</i> , 2012 , 7, 243-246	1.5	3

21	Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, 548-53	2.2	10
20	Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. <i>Molecular Genetics and Metabolism</i> , 2011 , 104, 167-73	3.7	43
19	Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. <i>Arthritis and Rheumatism</i> , 2011 , 63, 713-21		430
18	Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. <i>Chest</i> , 2010 , 138, 1464-74	5.3	233
17	A survey of rheumatologistsPpractice for prescribing pneumocystis prophylaxis. <i>Journal of Rheumatology</i> , 2010 , 37, 792-9	4.1	29
16	Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. <i>Current Rheumatology Reviews</i> , 2010 , 6, 108-119	1.6	55
15	Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 623-6	5.3	14
14	A rare cause of cardiac ischemia: systemic lupus erythematosus presenting as the hyperviscosity syndrome. <i>Annals of Internal Medicine</i> , 2010 , 153, 422-4	8	2
13	Drug-related myopathies of which the clinician should be aware. <i>Current Rheumatology Reports</i> , 2010 , 12, 213-20	4.9	82
12	Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. <i>Arthritis Care and Research</i> , 2010 , 62, 1328-34	4.7	148
11	A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2757-66		321
10	Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. <i>Chest</i> , 2009 , 135, 1550-1556	5.3	116
9	Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. <i>Journal of Rheumatology</i> , 2008 , 35, 84-90	4.1	18
8	Renal biopsy in lupus patients with low levels of proteinuria. <i>Journal of Rheumatology</i> , 2007 , 34, 332-5	4.1	68
7	Screening for proteinuria in patients with lupus: a survey of practice preferences among American rheumatologists. <i>Journal of Rheumatology</i> , 2007 , 34, 973-7	4.1	7
6	Statin myopathy: an update. Current Opinion in Rheumatology, 2006, 18, 647-53	5.3	36
5	Adult inflammatory myopathies. Best Practice and Research in Clinical Rheumatology, 2004, 18, 331-44	5.3	35
4	Myositis: an update on pathogenesis. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 700-6	5.3	24

LIST OF PUBLICATIONS

3	Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. <i>Journal of Rheumatology</i> , 2004 , 31, 1557-9	4.1	54
2	Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. <i>Journal of Rheumatology</i> , 2003 , 30, 2725-7	4.1	16
1	Ultra-Efficient Short Read Sequencing of T Cell Receptor Repertoires		1